Login
$SIBN
$23.41 -$0.03 (0.13%) Live

$SIBN 8-K SEC Filings

Filed On Filing
02 Nov 2026 8-K: Results of Operations and Financial Condition

Delivered ~20% U.S. procedure volume growth in the third quarter

11 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

03 Aug 2026 8-K: Results of Operations and Financial Condition

Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA

08 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

11 May 2026 8-K: Results of Operations and Financial Condition

Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA

23 Feb 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The statements in this presentation regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, are “forward-looking” statements. These forward-loo...

10 Nov 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter

04 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven

06 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

A total of 37,674,856 shares of the Company’s common stock were present or represented by proxy at the Annual Meeting, which represented approximately 89% of the Company’s 42,529,059 shares of common stock that were outstanding and entit...

05 May 2025 8-K: Results of Operations and Financial Condition

Achieved ~25% worldwide revenue growth and positive adjusted EBITDA

24 Feb 2025 8-K: Results of Operations and Financial Condition

Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024

13 Jan 2025 8-K: Results of Operations and Financial Condition

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%

12 Nov 2024 8-K: Results of Operations and Financial Condition

Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024

05 Aug 2024 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Increases 2024 revenue guidance to $165 million - $167 million

19 Jul 2024 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made as of July 18, 2024, by and between BIXBY SPE FINANCE 11, LLC, a Delaware limited liability company (“Landlord”), and SI-BONE INC., a Delaware corporation (“Tenant”).

26 Jun 2024 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SI-BONE, INC.

06 May 2024 8-K: Results of Operations and Financial Condition

SANTA CLARA, Calif. May 6, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024.

26 Feb 2024 8-K: Results of Operations and Financial Condition

SANTA CLARA, Calif. February 26, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full yea...

08 Jan 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

This presentation contains “ forward-looking statements,” which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often co...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support